Leerink Partners maintains Veradermics at Outperform, raises price target to $150 from $135

Leerink Partners kept Veradermics at Outperform, raising its price target to $150 from $135, an 11.1% increase. This implies a 4.2% upside from the Nov 9 close of $143.95. Recent analyst targets range from $172 to $204.

Original reporting
Published Nov 9, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leerink Partners maintains Veradermics at Outperform, raises price target to $150 from $135 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Limited impact as the change is small and lacks supporting news.

02

Market read

Minor analyst rating change with minimal trading relevance.

03

What to watch

No new fundamental data accompanies the rating change.

Relevance 4/10Novelty 2/10Timing: today

Background

Analyst rating update for Veradermics with a modest price target increase.

Market effects

none

none

none

Counterpoint

The target raise is modest and may already be priced in.

Key entities

  • Veradermics

    Subject of the analyst rating update.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.